Erlotinib is a quinazoline derivative that selectively and reversibly inhibits the tyrosine kinase activity of the EGFR. Here, we review the mechanism(s) of action of erlotinib, as well as the ...
Careful management by a team of specialists is needed to balance disease control and fetal health in patients with CML who are pregnant or trying to become prengant.
Shenzhen Genuine Biotech Co. Ltd. has disclosed tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) allosteric inhibitors reported to be useful for the treatment of cancer.
ORR increased from 60.9% with osimertinib alone to 90.5% with the addition of the MET-selective tyrosine kinase inhibitor (TKI) savolitinib. The disease control rate increased from 87.0% with ...